0001213900-22-005367.txt : 20220204 0001213900-22-005367.hdr.sgml : 20220204 20220204080613 ACCESSION NUMBER: 0001213900-22-005367 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220204 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220204 DATE AS OF CHANGE: 20220204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SomaLogic, Inc. CENTRAL INDEX KEY: 0001837412 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 854298912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40090 FILM NUMBER: 22591033 BUSINESS ADDRESS: STREET 1: C/O CORVEX MANAGEMENT LP STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10065 BUSINESS PHONE: (212) 474 6724 MAIL ADDRESS: STREET 1: C/O CORVEX MANAGEMENT LP STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10065 FORMER COMPANY: FORMER CONFORMED NAME: CM Life Sciences II Inc. DATE OF NAME CHANGE: 20201221 8-K 1 ea154957-8k_somalogic.htm CURRENT REPORT
0001837412 false 0001837412 2022-02-04 2022-02-04 0001837412 SLGC:ClassCommonStock0.0001ParValuePerShareMember 2022-02-04 2022-02-04 0001837412 SLGC:WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2022-02-04 2022-02-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 4, 2022

 

SomaLogic, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40090   52-4298912

(State or other jurisdiction

of incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

2945 Wilderness Place, Boulder, Colorado   80301
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (303) 625-9000

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Class A common stock, $0.0001 par value per share   SLGC   The NASDAQ Stock Market LLC
Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share   SLGCW   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On February 4, 2022, SomaLogic, Inc. (the “Company”) issued a press release providing updated revenue guidance for the full fiscal year 2022. The Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

 

Also on February 4, 2022, members of the management team of the Company will host a virtual analyst and investor meeting. A live audio webcast of the presentation along with a copy of the Company presentation materials from the conference will be available through the investor page at the Company’s website: investors.somalogic.com.

 

The information in this Item 7.01 of this Current Report on Form 8-K and the exhibit hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation by reference language in such filing.

 

The Company’s actual results may differ materially from the preliminary information provided in the accompanying press release. Factors that could cause these preliminary estimates to differ include, but are not limited to, discovery of new information that alters expectations about such results or impacts valuation methodologies underlying such results.

 

This Current Report on Form 8-K and the accompanying press release contain certain forward-looking statements within the meaning of the federal securities laws, including statements relating to the expected future performance of the Company. These forward-looking statements, including the Company’s 2021 revenue outlook, are not historical and generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions that relate to the Company’s strategy, expectations, plans, or intentions. All statements the Company makes relating to its estimated and projected financial results or to its expectations regarding future trends are forward-looking statements.  In addition, the Company, through its senior management team, from time to time makes forward-looking public statements concerning its expected future operations and performance and other developments.  Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors.  Many factors could cause actual results events to differ materially from the forward-looking statements in this press release, including factors which are beyond the Company’s control. Investors should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Proxy Statement/Prospectus filed with the Securities and Exchange Commission (the “SEC”) on August 12, 2021 and the Company’s Current Report on Form 8-K filed with the SEC on September 8, 2021, as well as subsequent annual and periodic reports filed with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. All forward-looking information and subsequent written and oral forward-looking statements attributable to the Company, or to persons acting on its behalf, are expressly qualified in their entirety by the cautionary statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.  

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit Number

   Exhibit Description
99.1  

Press Release issued by SomaLogic, Inc. on February 4, 2022

104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SomaLogic, Inc.
  (Registrant)
     
  By: /s/ Roy Smythe
  Name:  Roy Smythe
  Title:  Chief Executive Officer

 

February 4, 2022

 

 2

 

 

 EX-99.1 2 ea154957ex99-1_somalogic.htm PRESS RELEASE ISSUED BY SOMALOGIC, INC. ON FEBRUARY 4, 2022

Exhibit 99.1

 

SomaLogic Provides 2022 Revenue Guidance in Conjunction with Analyst and Investor Meeting

 

BOULDER, Colo., February 4, 2022 (GLOBE NEWSWIRE) – SomaLogic, Inc., a leader in AI-data driven proteomics technology, will host a virtual analyst and investor meeting today, February 4th, 2022, from 10:00 a.m. to approximately 1:00 p.m. Eastern Time. The event is intended to highlight recent corporate updates, technical specifications and capabilities of the SomaScan platform, and various applications across life science tools and clinical diagnostics. SomaLogic management will be joined by leading experts and partners to discuss several ongoing initiatives demonstrating the vast potential for proteomics to deliver meaningful insights that can positively impact human health.

 

2022 Revenue Guidance

 

In conjunction with the event, SomaLogic is providing full-year 2022 revenue guidance. Management projects 2022 revenue of approximately $105 million to $110 million.

 

“We are excited about the strong revenue growth we have recognized over the past few years and our outlook for 2022,” said Roy Smythe, M.D., Chief Executive Officer of SomaLogic. “We are growing the size of our commercial team substantially and diversifying our unique offerings for our customers and collaborators. These successful efforts, along with the rapidly increasing demand for proteomics solutions and services means the future is incredibly bright for SomaLogic.”

 

Note, in early January SomaLogic announced expectations for 2021 revenues to exceed $79 million, the high-end of prior guidance. SomaLogic will announce final fourth quarter and full-year 2021 results during its earnings call in March.

 

Analyst and Investor Meeting

 

A live and archived webcast of the analyst and investor meeting is available on the “Investors” section of the company’s website at https://investors.somalogic.com.

 

About SomaLogic

 

SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

 

The SomaScan Platform is for Research Use Only (RUO) and has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic or patient management purposes.

 

 

 

 

 

Forward Looking Statements

 

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements relating to the expected future performance of the Company. These forward-looking statements, including our 2022 revenue outlook, are not historical and generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions that relate to our strategy, expectations, plans, or intentions. All statements we make relating to our estimated and projected financial results or to our expectations regarding future trends are forward-looking statements. In addition, we, through our senior management team, from time to time make forward-looking public statements concerning our expected future operations and performance and other developments. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual results and events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Proxy Statement/Prospectus filed with the Securities and Exchange Commission (the “SEC”) on August 12, 2021 and our Current Report on Form 8-K filed with the SEC on September 8, 2021, as well as subsequent annual and periodic reports filed with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. All forward-looking information and subsequent written and oral forward-looking statements attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety by the cautionary statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. SomaLogic does not give any assurance that the company will achieve its expectations.

 

SomaLogic Contact

Emilia Costales

720-798-5054

ecostales@somalogic.com

 

Investor Contact

Marissa Bych

Gilmartin Group LLC

investors@somalogic.com

 

 

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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slgc-20220204.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 slgc-20220204_def.xml XBRL DEFINITION FILE EX-101.LAB 6 slgc-20220204_lab.xml XBRL LABEL FILE Class of Stock [Axis] Class A common stock, $0.0001 par value per share Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 slgc-20220204_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Cover
Feb. 04, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 04, 2022
Entity File Number 001-40090
Entity Registrant Name SomaLogic, Inc.
Entity Central Index Key 0001837412
Entity Tax Identification Number 52-4298912
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2945 Wilderness Place
Entity Address, City or Town Boulder
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80301
City Area Code (303)
Local Phone Number 625-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
Class A common stock, $0.0001 par value per share  
Title of 12(b) Security Class A common stock, $0.0001 par value per share
Trading Symbol SLGC
Security Exchange Name NASDAQ
Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share  
Title of 12(b) Security Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share
Trading Symbol SLGCW
Security Exchange Name NASDAQ
XML 9 ea154957-8k_somalogic_htm.xml IDEA: XBRL DOCUMENT 0001837412 2022-02-04 2022-02-04 0001837412 SLGC:ClassCommonStock0.0001ParValuePerShareMember 2022-02-04 2022-02-04 0001837412 SLGC:WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2022-02-04 2022-02-04 iso4217:USD shares iso4217:USD shares 0001837412 false 8-K 2022-02-04 SomaLogic, Inc. DE 001-40090 52-4298912 2945 Wilderness Place Boulder CO 80301 (303) 625-9000 false false false false Class A common stock, $0.0001 par value per share SLGC NASDAQ Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share SLGCW NASDAQ true true EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 3 122 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://somalogic.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea154957-8k_somalogic.htm ea154957ex99-1_somalogic.htm slgc-20220204.xsd slgc-20220204_def.xml slgc-20220204_lab.xml slgc-20220204_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea154957-8k_somalogic.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 3, "dts": { "definitionLink": { "local": [ "slgc-20220204_def.xml" ] }, "inline": { "local": [ "ea154957-8k_somalogic.htm" ] }, "labelLink": { "local": [ "slgc-20220204_lab.xml" ] }, "presentationLink": { "local": [ "slgc-20220204_pre.xml" ] }, "schema": { "local": [ "slgc-20220204.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 65, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 122, "memberCustom": 2, "memberStandard": 0, "nsprefix": "SLGC", "nsuri": "http://somalogic.com/20220204", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea154957-8k_somalogic.htm", "contextRef": "From2022-02-04to2022-02-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://somalogic.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea154957-8k_somalogic.htm", "contextRef": "From2022-02-04to2022-02-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "SLGC_ClassCommonStock0.0001ParValuePerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A common stock, $0.0001 par value per share" } } }, "localname": "ClassCommonStock0.0001ParValuePerShareMember", "nsuri": "http://somalogic.com/20220204", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "domainItemType" }, "SLGC_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each exercisable for one share of Class A common stock at an exercise price of $11.50 per share" } } }, "localname": "WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember", "nsuri": "http://somalogic.com/20220204", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://somalogic.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001213900-22-005367-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-005367-xbrl.zip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end